23andMe Holding Co. (ME)
After hours:
| Previous close | 0.4937 |
| Open | 0.4820 |
| Bid | 0.3404 x 200 |
| Ask | 0.4735 x 2000 |
| Day's range | 0.4664 - 0.4940 |
| 52-week range | 0.3500 - 2.2100 |
| Volume | |
| Avg. volume | 7,625,932 |
| Market cap | 225.571M |
| Beta (5Y monthly) | 1.28 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Barrons.com
23andMe CEO Anne Wojcicki Says She’s Weighing Buyout Bid
In what looks like a potentially downbeat ending to 23andMe journey as a public company, founder and CEO Anne Wojcicki has offered to take the DNA testing business private. Wojcicki, who controls more than 20% of 23andMe’s stock, with about 49% voting control, told the company that she is considering making an offer to buy the shares she doesn’t already own. Neither Wojcicki nor the company have commented on what she might be willing to pay, but investors appear skeptical that it will come at a premium price.
- Bloomberg
23andMe Jumps as CEO Floats Taking DNA Tester Private
(Bloomberg) -- DNA testing firm 23andMe Holding Co.’s shares soared after Chief Executive Officer Anne Wojcicki said she’s considering taking the struggling company private, less than three years after it began selling shares.Most Read from BloombergDubai Grinds to Standstill as Flooding Hits CityElon Wants His Money BackSingapore Loses ‘World’s Best Airport’ Crown to QatarRecord Rainfall in Dubai? Blame Climate Change, Not Cloud SeedingRed Lobster Considers Bankruptcy to Deal With Leases and La
- Reuters
23andMe CEO Wojcicki considering taking firm private, filing shows
Last week, Wojcicki notified members of the board's special committee that she is considering a potential go-private transaction for 23andMe and indicated that she would begin speaking to partners and financing sources. 23andMe declined to comment on the filing and Wojcicki did not immediately respond to a Reuters' request for comment. 23andMe, best known for its saliva-based test kits that offer users a glimpse into their genetic ancestry went public in 2021 through a blank-check firm, backed by Virgin Group founder Richard Branson, in a deal that valued the merged entity at $3.5 billion.
